Nightly glass of wine may not be as harmless as many people think, study suggests

 I'm not concerned. What about all this? Your competent? doctor won't do a bit of thinking, just state; no alcohol!

Men must drink with male friends twice a week to stay healthy, study finds

 Do not bring this to your doctor's attention, you don't want to be responsible for an exploding head.

An occasional drink doesn't hurt coronary arteries

Smarter People Tend To Drink More Alcohol March 2019

Can alcohol make men smarter? Study suggests yes April 2012 

But what if you are using Guinness for blood thinning?

Guinness could really be good for you

A pint of the black stuff a day may work as well as a low dose aspirin to prevent heart clots that raise the risk of heart attacks.

Don't do this on your own, you know how deadly even one glass of alcohol is.

Why Do Moderate Drinkers Live Longer Than Abstainers? 

Man Dies Aged 107, Thanked Red Wine For Long Life - 3 liters a day, no water

So I'm looking at this 107 year old drinking 3 liters of wine a day and want to emulate him. Does your doctor have any proven scientific reason not to do this?

Here is what your doctor will use, no thinking required:

Safest level of alcohol consumption is none, worldwide study shows

The latest here:

Active people more likely to be heavy drinkers because they reward exercise with alcohol

The latest here:

Nightly glass of wine may not be as harmless as many people think, study suggests

A new study is challenging the conventional wisdom that a small, daily dose of alcohol might be good for your health.

The research, published in the Journal of Studies on Alcohol and Drugs, suggests that the safest amount of alcohol to consume is actually none at all. If adults do choose to drink, the team of scientists recommends setting a limit of one per day.

This challenges older guidelines, which often suggested that up to two daily drinks for men was a safe limit.

ALCOHOL DEATHS HAVE MORE THAN DOUBLED IN RECENT YEARS, ESPECIALLY AMONG WOMEN

"While the new U.S. Dietary Guidelines contain a useful ‘less-is-best’ message, they provide no quantitative framework," study co-author Timothy Naimi, director of the University of Victoria’s Canadian Institute for Substance Use Research, said in a press release.

"Our study was designed to do just that across the drinking spectrum."

READ ON THE FOX NEWS APP

Researchers analyzed data on alcohol-related injuries and illnesses and compared it with large national health and demographic databases. iStock© iStock

Researchers reached their conclusions by analyzing data on alcohol-related injuries and illnesses and comparing it with large national health and demographic databases, according to a press release.

Using statistical models, they examined how regular alcohol consumption is linked to life expectancy.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

"Even low levels of alcohol use come with health risks," lead study author Kevin Shield, an associate professor at the University of Toronto, in the same press release. "And that risk continues to increase the more someone drinks."

After evaluating the cumulative risks for conditions like liver disease, stroke and certain cancers, the study suggests that the assumed benefits of drinking are heavily outweighed by the potential dangers.

Even low levels of alcohol use come with health risks, according to the researchers. iStock© iStock

For those looking to protect their long-term health, researchers emphasized that cutting back to one drink or giving up alcohol entirely appears to be the best strategy.

Dr. Marc Siegel, Fox News senior medical analyst, noted that this was an observational Canadian study looking at U.S. census data.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

"It is massive, but still not proof," cautioned Siegel, who was not involved in the study. "I am impressed with the endpoint, which is to assess alcohol-specific mortality," he added.

The doctor called the research "convincing" in terms of showing that even lower levels of drinking carry mortality risk.

For those looking to protect their long-term health, researchers recommend cutting back to one drink or giving up alcohol altogether. iStock© iStock

"We are in the process of debunking previous research and public health statements that a small amount of alcohol is actually good for you, and replacing it with the more realistic and accurate notion that no amount of alcohol is good," he told Fox News Digital.

CLICK HERE FOR MORE HEALTH STORIES

Alcohol affects multiple systems throughout the body, acting as a toxin that can compromise vital organs over time, according to the doctor.

Siegel warned that "alcohol is bad for the heart, the liver and the brain, and it increases inflammation and certain cancers, all of which lead to increased mortality risks."

Alcohol affects multiple systems throughout the body, acting as a toxin that can compromise vital organs over time, according to a doctor. iStock© iStock

While the research offers an overview of public health trends, it is an observational study based on U.S. census data, meaning it can only show strong correlations and cannot prove direct cause and effect, the researchers acknowledged.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Additionally, because the study relies on self-reported drinking habits, it is subject to the common limitation of individuals underestimating or misreporting their actual alcohol consumption.

Original article source: Nightly glass of wine may not be as harmless as many people think, study suggests

Dietary Thiamine Linked With Cognition — J-shaped curve emerges between vitamin B1 in diet and cognitive decline

Ask your competent? doctor PRECISELY what you should do with this. Don't try to figure this out yourself, your doctor is being paid to know this stuff. Your doctor should easily know how much thiamine you're getting in your hospital meals.

Dietary Thiamine Linked With Cognition J-shaped curve emerges between vitamin B1 in diet and cognitive decline

Dietary thiamine (vitamin B1) intake was linked with cognition in older adults, a longitudinal analysis in China suggested.

Over a median follow-up of 5.9 years, cognitive decline risk was minimal at dietary thiamine intake levels of 0.60 to 1.00 mg/day, reported Xianhui Qin, MD, of Southern Medical University in Guangzhou, and co-authors.

However, a J-shaped association emerged between intake of dietary thiamine and 5-year cognitive decline, with an inflection point at 0.68 mg/day (95% CI 0.56-0.80), the researchers wrote in General Psychiatryopens in a new tab or window.

Before the inflection point of 0.68 mg/day, thiamine intake was not significantly associated with cognitive decline. After the inflection point, each daily 1.0-mg increase in thiamine intake was associated with a drop of 4.24 points in global cognitive scores (95% CI 2.22-6.27) and 0.49 standard units in composite cognitive scores (95% CI 0.23-0.76) within 5 years (P<0.001 for both). Global cognitive scores could range from 0 to 27.

The association of dietary thiamine intake with cognitive decline beyond the inflection point appeared stronger in people with obesity or hypertension and in non-smokers, Qin and colleagues noted. After multiple test correction, the effect of hypertension and smoking became non-significant.

Food sources of thiamine include whole grains, meat, and fish. In the U.S., common thiamine sourcesopens in a new tab or window are cereals and bread. Several observational studies -- including a recent cross-sectional analysisopens in a new tab or window of National Health and Nutrition Examination Survey (NHANES) data -- have reported a linear relationship between dietary thiamine and cognitive function in older adults.

In animal models, thiamine deficiency produces many Alzheimer's-like changes, noted Gary Gibson, PhD, of the Burke Neurological Institute of Weill Cornell Medicine in White Plains, New York, who wasn't involved with the study.

"Evidence suggests that the decline is related to a reduced ability to transport thiamine," Gibson told MedPage Today. "Thus, brains of Alzheimer's disease patients and animal models can be thiamine-deficient despite normal intake."

In 2021, an exploratory clinical trialopens in a new tab or window led by Gibson suggested that pharmacological-grade benfotiamine, a thiamine prodrug not available commercially, may help people with mild cognitive impairment or mild Alzheimer's disease. A larger phase II studyopens in a new tab or window that randomizes people with early Alzheimer's disease to benfotiamine or placebo is underway.

In their analysis, Qin and co-authors used data from the China Health and Nutrition Surveyopens in a new tab or window. In 1997, 2000, 2004, and 2006, cognitively healthy participants ages 55 and older had assessments of mental acuity. Information about diet was collected in each survey round, supplemented by detailed data about dietary intake over 24 hours on 3 consecutive days, which were collected in person by trained investigators.

The study included 3,106 participants capable of completing repeated cognitive function tests who had at least two rounds of survey data. Mean age was 63, and the average dietary thiamine intake was 0.93 mg/day.

Cognitive decline was defined as the 5-year decline rate in global or composite cognitive scores based on a subset of items from the Telephone Interview for Cognitive Status-modified (TICS-mopens in a new tab or window), which can be administered by phone or in-person. The test included immediate and delayed recall of a 10-word list, counting backward from 20, and serial seven subtraction five times from 100 to evaluate verbal memory, attention, and calculation, respectively. Higher scores in each item indicated better function. The researchers also determined a composite score by averaging z scores of the test components.

Compared with participants with thiamine intake of 0.60 to less than 1.00 mg/day, β for 5-year decline rates in the composite cognitive score was 0.13, 0.15, and 0.33 in those with daily intake of less than 0.60 mg, 1.00 mg to less than 1.20 mg, and 1.20 mg or more, respectively. "Similar patterns were observed for the global cognitive scores," Qin and colleagues noted. "Moreover, multiple test correction had no significant effect on the results."

Other variables -- age, sex, alcohol consumption, and dietary intake of fat, protein, or carbohydrate -- did not significantly change the findings, the researchers added.

The analysis relied on dietary intake recalled over 24-periods, which may not be fully accurate, Qin and co-authors acknowledged. It assessed data about cognitively healthy older adults in China only and findings might not apply to others.

• Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

This study was funded by the National Key Research and Development Program of China and the National Natural Science Foundation of China.

Qin and co-authors reported no conflicts of interest.

Gibson reported relationships with the National Institute on Aging.

Primary Source

General Psychiatry

Source Reference: opens in a new tab or windowLiu C, et al "J-shaped association between dietary thiamine intake and the risk of cognitive decline in cognitively healthy, older Chinese individuals" Gen Psychiatr 2024; DOI: 10.1136/gpsych-2023-101311.

My stroke rehab schedule

This is not something any of you reading this should follow. None of this is sanctioned by any medical staff
I try to do this daily.
Since moving to an apartment in East Lansing, MI I have the ability to setup stroke stations and leave them up permanently. I work my way around the room.
Bosu, round side down - in the corner so I can touch the wall for balance.  At the gym when I first started this I used a railing.10-15 minutes just rolling the Bosu under your feet. Excellent for strengthening your ankles and general balance.
Cane1 -  handle in bad hand, good hand on rubber tip, push left hand straight out in front, then over the head and back down behind me, completing a complete circle. For my spasticity.
Cane2 - sitting in chair, bad hand on grip. Extend the arm directly out in front of you, pull it back in, 50 reps. When done, arm straight out, let it drop to the left, bring it upright,  let it drop to the right, bring it upright. 25 times each.
Theraband progressive hand trainer sheets
with prepunched holes for your fingers. You put the sheet into an embroidery hoop, the one that comes with the kit doesn't work, so buy a 7 or 9 inch embroidery hoop. none of the individual sheets were strong enough to keep my fingers open, so I used all six that came in the red refill pack and put them into one hoop.   I can get this on in 30 seconds. Not only can you  work flexion, also spreading/unspreading your fingers.
Saebo flex -Because the Saebo takes me 20 minutes to get on I don't use it very much.
Passive flexing and unflexing the fingers - This is done anytime my right hand is not in use for daily tasks.
Hand Helper - I received one of these from my OT and would spend minutes willing my hand to relax. Getting the rubber bands on requires a two-handed person.
 eStim -
Splitting wedge - This needs to be done on a carpeted floor, its too dangerous anywhere off the ground. I force the top end into my left hand and just balance it pointed side down, at first with my elbow on the floor, don't try this unless you have the ability to release your hand  before it tips and hits the floor, its quite painful  otherwise.
Gripmaster I bought a couple of light resistance ones but they don't work for me because I can't separate my fingers enough to use them.
Hamstring work, sitting in regular kitchen chair pull your bad leg underneath you.
Laundry basket carrying   I load it up with clothes, if the left hand releases the falling to the floor does not hurt anything. Forcing my hand open to grab/release the handle will eventually(1 million tries later?) tell my extensors to work.

Study finds potential link between daily multivitamin and improved cognition in older adults

 Ask your doctor if the upside potential outweighs the downsides. Don't do anything with this until your doctor informs you of their analysis. Of course you have no clue what is in the vitamins you take.

The supplements in the US have zero guarantee of purity or efficacy due to the fucking stupidity of the US Congress passing the Dietary Supplement Health and Education Act of 1994 (DSHEA).

Study finds potential link between daily multivitamin and improved cognition in older adults

(CNN)Taking a daily multivitamin might be associated with improved brain function in older adults, a new study says, and the benefit appears to be greater for those with a history of cardiovascular disease.

The findings did not surprise the researchers -- rather, they were shocked, said Laura Baker, an author of the study and professor of gerontology and geriatric medicine at Wake Forest University in North Carolina.

"I have to use the word 'shocked,' " Baker said.

The researchers -- from the Wake Forest University School of Medicine, in collaboration with Brigham and Women's Hospital in Boston -- analyzed cognitive function in older adults who were assigned to take either a cocoa extract supplement containing flavonoids, a multivitamin or a placebo every day for three years. No one, not even the researchers, knew who was assigned to which daily routine until the results were revealed.

What to eat for a sharper mind 00:58

"We really believed that the cocoa extract was going to have some benefits for cognition based on prior reports of cardiovascular benefit. So we're waiting for that big reveal in our data analysis -- and it was not cocoa extract that benefited cognition but rather the multivitamin," Baker said. "We are excited because our findings have uncovered a new avenue for investigation -- for a simple, accessible, safe, inexpensive intervention that could have the potential to provide a layer of protection against cognitive decline."

But she added that she and her team are not ready to recommend that older adults immediately add a daily multivitamin to their routine based on these results alone.

The findings, published Wednesday in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, are not definitive and cannot be generalized to the public. More research is needed to confirm them.

"It's too soon to make these recommendations," Baker said. "I feel like we need to do this in one other study."

Finding connections in brain health

The new study included 2,262 people, 65 and older, who were enrolled between August 2016 and August 2017 and followed for three years. The participants completed tests over the phone annually to evaluate their cognitive function. They were scored on recalling stories, showing verbal fluency and ordering digits, among other tests.

The researchers analyzed function, based on test scores, among those who took cocoa extract daily compared with a placebo, and among those who took the daily multivitamin compared with a placebo.

The researchers found that three years of taking the multivitamin appeared to have slowed cognitive aging by 1.8 years, or 60%, compared with the placebo. Daily cocoa extract supplementation for three years did not affect cognitive function, the researchers wrote.

Are you wasting your money on supplements? Most likely, experts say

The study -- supported by the National Institute on Aging of the National Institutes of Health -- also found that multivitamins were most beneficial for older adults who had a history of cardiovascular disease.

"It's well-known that those with cardiovascular risk factors could have lower levels in their blood of vitamins and minerals. So supplementing those vitamins and minerals could improve cardiovascular health and, by virtue of that, improve cognitive health -- and we know that there's a strong connection between cardiovascular health and brain health," said Dr. Keith Vossel, a professor of neurology and director of the Mary S. Easton Center for Alzheimer's Research and Care at the University of California, Los Angeles.

Thanks to that connection between cardiovascular and brain health, taking steps to prevent cardiovascular disease or other chronic diseases -- such as maintaining a healthy diet and exercise -- can benefit the brain too, said Vossel, who was not involved in the new study.

"If we can really eliminate or really prevent chronic diseases, we could prevent dementias," he said. "Roughly up to 40% of dementia could be prevented with just better preventative measures throughout life's span."

Cognitive decline linked to ultraprocessed food, study finds

The specific factors driving this link between a multivitamin and cognitive function are unclear and require more research, but Baker and her team think the findings might be connected to the way multivitamins can benefit people who might be lacking in micronutrients such as vitamin C, vitamin E, magnesium or zinc.

"With aging, the situation can get worse. A lot of our older adults do not have adequate nutrition for a number of reasons," Baker said.

"As we get older, we are more likely to have medical conditions that can compromise micronutrient sufficiency," she said. "The medications that we take for these conditions can also affect micronutrient sufficiency by interfering with the body's ability to absorb these essential nutrients from the diet."

'We've been down this road a little before'

Other studies have had mixed results in the association between certain vitamins and supplements and dementia risk, Vossel warned.

How safe are supplements? 02:58

"We've been down this road a little before with vitamins and dementia research. For many years, dementia specialists were recommending vitamin E based on some early promising results with vitamin E and cognition, and especially those with Alzheimer's disease. But then, the results have been mixed since then," Vossel said.

Older adults should talk to their primary care physician before starting a vitamin or supplement routine, he added.

"Supplementing is usually safe, but it needs to be monitored carefully, especially for those who have memory loss, because overdosing with vitamins can be very dangerous," Vossel said. "Even with vitamin E overdosing or taking high levels of vitamin E can increase the risk of bleeding. So these are just some considerations."

Get CNN Health's weekly newsletter

Overall, the new study's findings are encouraging, said Heather Snyder, vice president of medical and scientific relations at the Alzheimer's Association.

"There's certainly follow-up work that we need to see happen -- particularly independent confirmation in studies that are in larger and more diverse populations -- but this is encouraging," she said. "There is more research that needs to be done to understand what it might be in the multivitamin that may have a benefit."

Statins, Enzyme CoQ10 Supplement Use, and Cognitive Functioning

 Well, CoQ10 is listed in this; but unless your doctor prescribes don't do anything.

Top 7 Vitamins for Stroke Recovery, Backed by Science from Flint Rehab

 February 2020

The latest here:

Statins, Enzyme CoQ₁₀ Supplement Use, and Cognitive Functioning

Brian G. Collin, MA, PhD, Dheeraj Raju, MSIE, PhD, Steven Katsikas, PhD

First Published September 8, 2021 Research Article Find in PubMed 

https://doi.org/10.1177/08919887211044747

Article information

Abstract

Objective:

The current study assessed the effects of statin and CoQ₁₀ supplement use on changes in cognitive functioning in the Wisconsin Registry for Alzheimer’s Prevention study.

Methods:

1,573 subjects were administered medical histories, the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test (RAVLT), Wechsler Memory Scale, Logical Memory subtest, and the Trail Making Test, Parts A (TMT-A) and B (TMT-B) 3-4 times over 5-10 years.

Results:

Linear mixed models did not yield significant effects for statin or CoQ₁₀ supplement use on changes in mental status, learning and memory, psychomotor speed, and cognitive flexibility.

Conclusions:

Statin and/or CoQ₁₀ supplement use was not associated with neuropsychological test performance in the Wisconsin Registry for Alzheimer’s Prevention study.

Keywords

statin, auditory memory, cognitive flexibility, psychomotor speed, dementia, CoQ₁₀, Alzheimer’s disease

Access Options

Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling

 DO NOT DO THIS! This is in mice and human testing likely will never occur. I see no proof this actually helped neuroplasticity. Neuroplasticity signaling doesn't mean neuroplasticity actually occurred.

Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling

Author links open overlay panelAntonioInserra^aAntonellaCampanale^aDavidCheishvili^bcSergiyDymov^dAmyWong^eNathalieMarcal^fRobert AndrewSyme^gLorneTaylor^eDaniloDe Gregorio^a1Timothy E.Kennedy^fMosheSzyf^dGabriellaGobbi^a

https://doi.org/10.1016/j.pnpbp.2022.110594Get rights and content

Highlights

•

Repeated LSD administration affects the DNA methylation level of genes involved with neurotropic, neurotrophic, and neuroplasticity signaling.

•

Repeated LSD administration affects the protein level of genes involved with neurotropic, neurotrophic, and neuroplasticity signaling.

•

Repeated LSD administration increases the transcription level of genes involved with neurotropic, neurotrophic, and neuroplasticity signaling detected as both differentially methylated, and differentially expressed.

•

This could represent a core mechanism mediating the effects of psychedelics.

Abstract

Aim

Psychedelic compounds elicit relief from mental disorders. However, the underpinnings of therapeutic improvement remain poorly understood. Here, we investigated the effects of repeated lysergic acid diethylamide (LSD) on whole-genome DNA methylation and protein expression in the mouse prefrontal cortex (PFC).

Methods

Whole genome bisulphite sequencing (WGBS) and proteomics profiling of the mouse prefrontal cortex (PFC) were performed to assess DNA methylation and protein expression changes following 7 days of repeated LSD administration (30 μg/kg/day); a treatment we previously found to potentiate excitatory neurotransmission and to increase dendritic spine density in the PFC in mice. qRT-PCR was employed to validate candidate genes detected in both analyses.

Results

LSD significantly modulated DNA methylation in 635 CpG sites of the mouse PFC, and in an independent cohort the expression level of 181 proteins. Gene signaling pathways affected are involved in nervous system development, axon guidance, synaptic plasticity, quantity and cell viability of neurons and protein translation. Four genes and their protein product were detected as differentially methylated and expressed, and their transcription was increased. Specifically, Coronin 7 (Coro7), an axon guidance cue; Penta-EF-Hand Domain Containing 1 (Pef1), an mTORC1 and cell cycle modulator; Ribosomal Protein S24 (Rps24), required for pre-rRNA maturation and biogenesis of proteins involved with cell proliferation and migration, and Abhydrolase Domain Containing 6, Acylglycerol Lipase (Abhd6), a post-synaptic lipase.

Conclusions

LSD affects DNA methylation, altering gene expression and protein expression related to neurotropic-, neurotrophic- and neuroplasticity signaling. This could represent a core mechanism mediating the effects of psychedelics.

Data availability

Data will be made available on request.

Cited by (0)

¹

Current address: Vita-Salute San Raffaele University, Division of Neuroscience, Milan, Italy.

View full text

Promising Action of Cannabinoids on ER Stress-Mediated Neurodegeneration: An In Silico Investigation

 Don't read between the lines and think that cannabidiol or marijuana would suffice in duplicating the benefits. You're going to have to wait 50 years before anything gets defined for layperson use. Hope you last that long.

Promising Action of Cannabinoids on ER Stress-Mediated Neurodegeneration: An In Silico Investigation

Volume 41, Issue 4, 2022, pp. 39-54

DOI: 10.1615/JEnvironPatholToxicolOncol.2022040055

Get access

Fathima Hajee Basha
School of Life Sciences, B.S Abdur Rahman Crescent Institute of Science of Technology, Vandalur, Chennai 600048, Tamil Nadu, India

Mohammad Waseem
School of Life Sciences, B.S Abdur Rahman Crescent Institute of Science of Technology, Vandalur, Chennai 600048, Tamil Nadu, India

Hemalatha Srinivasan
School of Life Sciences, B.S Abdur Rahman Crescent Institute of Science of Technology, Vandalur, Chennai 600048, Tamil Nadu, India

ABSTRACT

Neurodegeneration has been recognized as a clinical episode characterized by neuronal death, including dementia, cognitive impairment and movement disorder. Most of the neurodegenerative deficits, via clinical symptoms, includes common pathogenic features as protein misfolding and aggregation. Therefore, the focus highlights the cellular organelle endoplasmic reticulum (ER) critically linked with the quality control and protein homeostasis. Unfolded protein response (UPR) or ER stress have also been considered as hallmarks for neurodegenerative disorders. It has been implicated that the levels of endocannabinoids (ECB) could rise at the platform of neurodegeneration. In addition, phytocannabinoids (PCB) including cannabidiol (CBD) could also initiate the IRE1, PERK, XBP-1, and ATF6, pathways that could lead to the degradation of the misfolded proteins and termination of protein translation. Thus, our aim was to determine if cannabinoids bind to these ER arm proteins involved in UPR by molecular docking and therefore determine its drug resemblance through ADME analysis. In our study, three cannabinoid receptors (CB₁, CB₂, and CB₃) were considered to demonstrate their neuroprotective actions. The chosen ligands were screened as PCB (Δ9-tetrahydrocannabinol or THC), CBD, and two ECB, anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The current findings have advocated that the cannabinoids and their molecular targets have shown considerable binding and their ADME properties also reveals that they possess moderate drug-like properties making it as a valuable option for the treatment and management of neurodegenerative diseases.

KEY WORDS: neurodegeneration, ER stress, cannabinoids, molecular docking, ADME

REFERENCES

1. Batista P, Pereira A. Quality of life in patients with neuro-degenerative diseases. J Neurol Neurosci. 2016;7(1):1-7.

2. Faden AI, Stoica B. Neuroprotection: Challenges and opportunities. Arch Neurol. 2007;64(6):794-800.

3. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S207-9.

4. Basha FH, Waseem M, Srinivasan H. Cellular and molecular mechanism in neurodegeneration: Possible role of neuroprotectants. Cell Biochem Funct. 2021;39(5): 11. 613-22.

5. Marsh AP. Molecular mechanisms of proteinopathies across neurodegenerative disease: A review. Neurol Res Pract. 2019;1(1):1-7.

6. Watson RR, Preedy VR. Bioactive nutraceuticals and dietary supplements in neurological and brain disease. In: Watson R, Preedy V, editors. Prevention therapy. Academic Press; 2015. p. 495-500.

7. Xiang C, Wang Y, Zhang H, Han F. The role of endoplasmic reticulum stress in neurodegenerative disease. Apoptosis. 2017;22(1):1-26.

8. Lou G, Palikaras K, Lautrup S, Scheibye-Knudsen M, Tavernarakis N, Fang EF. Mitophagy and neuroprotection. Trends Mol Med. 2020;26(1):8-20.

9. Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol. 2017;13(8): 477-91.

10. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: Pathogenesis and therapy. Brain Pathol. 2018;28(1):3-13.

11. Adams CJ, Kopp MC, Larburu N, Nowak PR, Ali MMU. Structure and molecular mechanism of ER stress signaling by the unfolded protein response signal activator IRE1. Front Mol Biosci. 2019;6:11.

12. Scheper W, Hoozemans JJM. The unfolded protein response in neurodegenerative diseases: A neuropathological perspective. Acta Neuropathol. 2015;130(3):315-31.

13. Milano W, Capasso A. Neuroprotection by cannabinoids in neurodegenerative diseases. Alzheimer's. Dement Cogn Neurol. 2018;2(1):1-7.

14. Giammalva GR, Iacopino DG, Graziano F, Guli C, Pino MA, Maugeri R. Clinical and radiological features of Forestier's disease presenting with dysphagia. Surg Neurol Int. 2018;28;9:236.

15. Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S. Endocannabinoid system in neurodegenerative disorders. J Neurochem. 2017;142(5):624-48.

16. Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1-37.

17. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010;160(3):480-98.

18. Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S, Avolio C, Serviddio G. From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11:124.

19. Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, Wang Y, Liang C. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. Eur J Med Chem. 2020;192:112163.

20. Dash R, Jahan I, Munni YA. Roles of cannabidiol in reversing proteinopathies roles of cannabidiol in reversing proteinopathies. Ageing Res Rev. 2020;65:101209.

21. Yang H, Zhou J, Lehmann C. GPR55 - A putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27(3):297-302.

22. Tuduri E, Imbernon M, Hernandez-Bautista RJ, Tojo M, Fern0 J, Dieguez C, Nogueiras R. Gpr55: A new promising target for metabolism? J Mol Endocrinol. 2017;58(3):R191-202.

23. Guerrero-Alba R, Barragan-Iglesias P, Gonzalez-Hernandez A, Valdez-Morales EE, Granados-Soto V, Condes-Lara M, Rodriguez MG, Marichal-Cancino BA. Some prospective alternatives for treating pain: The endocannabinoid system and its putative receptors GPR18 and GPR55. Front Pharmacol. 2019;8(9):1496.

24. Cooray R, Gupta V, Suphioglu C. Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson's and Alzheimer's diseases: A review. Mol Neurobiol. 2020;57(11):4878-90.

25. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2017;152(7):1092-101.

26. Kruger A, Gonjalves Maltarollo V, Wrenger C, Kronen berger T. ADME profiling in drug discovery and a new path paved on silica. Drug Discov Dev. Cambrex High Point, Inc.; 2020.

27. Wang Y, Xing J, Xu Y, Zhou N, Peng J, Xiong Z, Liu X, Luo X, Luo C, Chen K, Zheng M, Jiang H. In silico AD-ME/T modelling for rational drug design. Q Rev Biophys. 2015;48(4):488-515.

28. Chen L, Li Y, Zhao Q, Peng H, Hou T. ADME evaluation in drug discovery. 10. Predictions of B-glycoprotein inhibitors using recursive partitioning and naive bayesian classification techniques. Mol Pharm. 20ll;8(3): 889-900.

29. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov. 2912;7(10):863-75.

30. Delaney JS. ESOL: Estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci. 2004;44(3):1000-5.

31. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.

32. Cristopher L. Lead profiling lead - and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337-41.

33. Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the rule of 5 and drugability. Adv Drug Deliv Rev. 2016;101: 89-98.

34. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;3(7):42717.

35. Daina A, Zoete V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117-21.

36. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.

37. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6(11):881-90.

38. Lipinski CA. Compound properties and drug quality. In: The practice of medicinal chemistry, 2nd ed. New York: Elsevier; 2003. p. 341-9.

39. Husain A, Ahmad A, Khan SA, Asif M, Bhutani R, Al-Abbasi FA. Synthesis, molecular properties, toxicity and biological evaluation of some new substituted imidazolidine derivatives in search of potent anti-inflammatory agents. Saudi Pharm J. 2016;24(1):104-14.

40. Rajasekaran S, Prasad P, Rao GK. iMedPub Journals Molecular Properties and Bio-Activity Score of 2 {[2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl]amino}-N-(substitutedphenyl) acetamides. Int J Drug Dev Res. 2020;3:12-4.